IA
RVLP

Insight Advisors’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Insight Advisors’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-75,646
Closed -$6.55K – 296
2023
Q3 		$6.55K Hold
75,646
– – ﹤0.01% 276
2023
Q2 		$42.4K Hold
75,646
– – 0.01% 282
2023
Q1 		$86.2K Buy
75,646
+37,823
+100% +$45.4K 0.02% 293
2022
Q4 		$43.5K Hold
37,823
– – 0.02% 312
2022
Q3 		$79K Hold
37,823
– – 0.03% 278
2022
Q2 		$59K Hold
37,823
– – 0.02% 298
2022
Q1 		$64K Buy
37,823
+13,023
+53% +$18.6K 0.02% 313
2021
Q4 		$27K Hold
24,800
– – 0.01% 311
2021
Q3 		$45K Hold
24,800
– – 0.01% 312
2021
Q2 		$85K Hold
24,800
– – 0.03% 307
2021
Q1 		$71K Buy
24,800
+10,000
+68% +$41.1K 0.02% 327
2020
Q4 		$61K Buy
+14,800
New +$85.3K 0.02% 266

Other funds holding RVLP

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Insight Advisors's RVLP Position: Q4 2023 in Review

Insight Advisors sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2023, closing a stake of 75,646 shares — an estimated $6.55K sold.

Insight Advisors first reported a position in RVLP in Q4 2020 and held it in 12 quarters. The position peaked at $86.2K in Q1 2023. 3 funds tracked by Wall St. Rank hold RVLP as of Q4 2023.

  • Insight Advisors reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Insight Advisors sold 75,646 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2023, an estimated $6.55K.
  • Insight Advisors first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2020 and held it in 12 quarters.
  • Insight Advisors's RVL Pharmaceuticals plc Ordinary Shares position peaked at $86.2K in Q1 2023.
  • 3 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2023.

Based on Insight Advisors's 13F filing for Q4 2023, filed 23 Jan 2024.